Regulus Therapeutics Inc. (NASDAQ:RGLS) Given Average Rating of “Moderate Buy” by Analysts

Regulus Therapeutics Inc. (NASDAQ:RGLS) has been assigned an average rating of “Moderate Buy” from the six ratings firms that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $10.80.

A number of research firms recently issued reports on RGLS. StockNews.com upgraded shares of Regulus Therapeutics to a “sell” rating in a research note on Tuesday, September 17th. Oppenheimer reaffirmed an “outperform” rating and issued a $7.00 price target on shares of Regulus Therapeutics in a research report on Wednesday, August 14th. Finally, HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of Regulus Therapeutics in a research note on Monday, November 11th.

Regulus Therapeutics Stock Performance

Shares of NASDAQ RGLS opened at $1.64 on Friday. The business’s 50-day simple moving average is $1.53 and its 200-day simple moving average is $1.74. Regulus Therapeutics has a 52 week low of $1.08 and a 52 week high of $3.79. The firm has a market cap of $107.42 million, a price-to-earnings ratio of -1.53 and a beta of 1.63.

Regulus Therapeutics (NASDAQ:RGLS) last released its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.03). As a group, equities research analysts forecast that Regulus Therapeutics will post -0.88 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in RGLS. Creative Planning bought a new position in Regulus Therapeutics during the third quarter valued at about $26,000. SG Americas Securities LLC acquired a new stake in shares of Regulus Therapeutics during the 3rd quarter worth approximately $33,000. Jane Street Group LLC bought a new stake in shares of Regulus Therapeutics during the third quarter valued at approximately $46,000. Rhumbline Advisers acquired a new position in shares of Regulus Therapeutics in the second quarter valued at $136,000. Finally, Barclays PLC raised its stake in shares of Regulus Therapeutics by 285.2% in the third quarter. Barclays PLC now owns 84,477 shares of the biopharmaceutical company’s stock valued at $132,000 after purchasing an additional 62,549 shares in the last quarter. Institutional investors and hedge funds own 92.38% of the company’s stock.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.